Patents by Inventor Thomas A. Dineen

Thomas A. Dineen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES
    Publication number: 20240010652
    Abstract: The present disclosure provides compounds of Formula (I-0), pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFR? and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFR?. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
    Type: Application
    Filed: October 13, 2021
    Publication date: January 11, 2024
    Inventors: Thomas A. Dineen, Nicholas Lydon
  • COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES
    Publication number: 20230391780
    Abstract: The present disclosure provides compounds of Formula (I), pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFR? and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFR?. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
    Type: Application
    Filed: October 13, 2021
    Publication date: December 7, 2023
    Inventor: Thomas A. Dineen
  • EGFR inhibitors
    Patent number: 11718602
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: August 8, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • MAP4K1 INHIBITORS
    Publication number: 20230140954
    Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
    Type: Application
    Filed: October 18, 2022
    Publication date: May 11, 2023
    Inventors: Jason D. Brubaker, Michael J. Burke, Joshua T. Close, Thomas A. Dineen, Joseph L. Kim, Chandrasekhar V. Miduturu, Emanuele Perola
  • MAP4K1 INHIBITORS
    Publication number: 20230112729
    Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
    Type: Application
    Filed: July 13, 2022
    Publication date: April 13, 2023
    Inventors: Jason D. Brubaker, Joshua T. Close, Thomas A. Dineen, Chandrasekhar V. Miduturu, Emanuele Perola
  • EGFR INHIBITORS
    Publication number: 20230056541
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 23, 2023
    Inventors: John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi
  • EGFR INHIBITORS
    Publication number: 20230026209
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: August 8, 2022
    Publication date: January 26, 2023
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • EGFR INHIBITORS
    Publication number: 20230019732
    Abstract: The present disclosure provides a compound represented by structural formula (I-0): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: August 9, 2022
    Publication date: January 19, 2023
    Inventors: Omar Ahmad, John Emmerson Campbell, Thomas A. Dineen, Meredith Suzanne Eno, Dilinie Prasadhini Fernando
  • MAP4K1 inhibitors
    Patent number: 11534441
    Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: December 27, 2022
    Assignee: Blueprint Medicines Corporation
    Inventors: Jason D. Brubaker, Chandrasekhar V. Miduturu, Michael J. Burke, Thomas A. Dineen, Joseph L. Kim, Joshua T. Close, Emanuele Perola
  • MAP4K1 INHIBITORS
    Publication number: 20220323438
    Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
    Type: Application
    Filed: January 14, 2021
    Publication date: October 13, 2022
    Inventors: Jason D. Brubaker, Chandrasekhar V. Miduturu, Michael J. Burke, Thomas A. Dineen, Joseph L. Kim, Joshua T. Close, Emanuele Perola
  • PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES
    Publication number: 20220153748
    Abstract: The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRa. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
    Type: Application
    Filed: April 8, 2020
    Publication date: May 19, 2022
    Inventors: Joseph L. Kim, Thomas A. Dineen, Timothy Guzi
  • Compositions and methods for treating KIT- and PDGFRA-mediated diseases
    Patent number: 10829493
    Abstract: The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFR? and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFR?. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: November 10, 2020
    Assignee: Blueprint Medicines Corporation
    Inventor: Thomas A. Dineen
  • COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES
    Publication number: 20200325141
    Abstract: The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFR? and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFR?. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 15, 2020
    Inventors: Thomas A. Dineen, Joseph L. Kim, Timothy Guzi
  • Alkynyl dihydroquinoline sulfonamide compounds
    Patent number: 10729684
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 4, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Thomas Dineen, Karina R. Vaida
  • ALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
    Publication number: 20200009129
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: July 12, 2019
    Publication date: January 9, 2020
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, Thomas DINEEN, Benjamin C. MILGRAM, Isaac E. MARX
  • Bicyclic ketone sulfonamide compounds
    Patent number: 10472356
    Abstract: The present invention provides compounds of Formula (I), wherein: as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 12, 2019
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Benjamin Charles Milgram, Thomas Dineen, John Stellwagen, Angel Guzman-Perez, Alessandro Boezio, Issac E. Marx
  • Alkyl dihydroquinoline sulfonamide compounds
    Patent number: 10383866
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 20, 2019
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Thomas Dineen, Benjamin C. Milgram
  • Tricyclic compounds and compositions as kinase inhibitors
    Patent number: 10377770
    Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 13, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Rajesh Karki, Savithri Ramurthy, Vivek Rauniyar, Richard Robinson, Patrick James Sarver
  • Compounds and compositions as RAF kinase inhibitors
    Patent number: 10167279
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 1, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Yan Lou, Gisele A. Nishiguchi, Savithri Ramurthy, Alice C. Rico, Vivek Rauniyar, Martin Sendzik, Sharadha Subramanian, Lina Quattrocchio Setti, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
  • ALKYNYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
    Publication number: 20180369226
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: December 19, 2016
    Publication date: December 27, 2018
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, Thomas DINEEN, Karina R. VAIDA